US14843C1053 - Common Stock
CASTLE BIOSCIENCES INC
NASDAQ:CSTL (5/8/2024, 7:00:00 PM)
After market: 23.54 0 (0%)23.54
-0.26 (-1.07%)
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 542 full-time employees. The company went IPO on 2019-07-25. The firm is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. The company also has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. Its products include DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix. DecisionDx-Melanoma is a gene expression profile test developed to identify the risk of metastasis in patients with invasive cutaneous melanoma.
CASTLE BIOSCIENCES INC
505 S Friendswood Drive, 2014 San Miguel Dr
Friendswood TEXAS 77546
P: 12817969032
CEO: Derek J. Maetzold
Employees: 542
Website: https://castlebiosciences.com/
CSTL stock results show that Castle Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Castle Biosciences (NASDAQ:CSTL) just reported results for the first quarter of...
Here you can normally see the latest stock twits on CSTL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: